XML 66 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue, Revenue recognised (Details) - GBP (£)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue recognitions [Abstract]        
Product revenue, net £ 45,514,000 £ 23,992,000 £ 87,566,000 £ 31,674,000
Pre-product revenue, net 0 3,708,000 0 6,537,000
Total revenue from sale of therapies 45,514,000 27,700,000 87,566,000 38,211,000
Collaboration revenue 2,250,000 4,302,000 4,739,000 16,265,000
Total revenue 47,764,000 32,002,000 92,305,000 54,476,000
United States [Member]        
Revenue recognitions [Abstract]        
Total revenue from sale of therapies 32,812,000 18,137,000 62,345,000 25,819,000
Europe [Member]        
Revenue recognitions [Abstract]        
Total revenue from sale of therapies 12,189,000 9,560,000 24,517,000 12,389,000
Rest of World [Member]        
Revenue recognitions [Abstract]        
Total revenue from sale of therapies 513,000 3,000 704,000 3,000
Eli Lilly [Member]        
Revenue recognitions [Abstract]        
Collaboration revenue 0 0 0 7,361,000
Genentech [Member]        
Revenue recognitions [Abstract]        
Collaboration revenue £ 2,250,000 £ 4,302,000 £ 4,739,000 £ 8,904,000